Transcriptome

Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid Biopsies with Machine Learning

Retrieved on: 
星期二, 十二月 6, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Research, Software, Artificial Intelligence, Genetics, Science, Clinical Trials, Prognosis, NGS, Diagnosis, GTC, Algorithm, Software, Degenerative disease, Transcriptome, Society, Health, Biomarker, Patient, DNA, Science, CFRNA, American Society of Hematology, LCA, Somatic mutation, Transplant, Nominal interest rate, Lymphoid neoplasms with plasmablastic differentiation, Nucleic acid thermodynamics, Artificial intelligence, Bone marrow, Cooperative, Machine learning, The, Lymphatic system, RNA, ASH, Primary central nervous system lymphoma, Birth control, Medical device

GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.

Key Points: 
  • GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.
  • Using cfRNA, GTC studies show that the cfRNA levels can be used in liquid immunoprofiling of hematologic neoplasms.
  • Combining this liquid immunophenotyping with machine learning algorithms report high reliability in the differential diagnosis between various types of lymphoid neoplasms/lymphoma.
  • The use of RNA profiling in tissue and liquid biopsies is opening new horizons in diagnostics, especially when combined with artificial intelligence.

Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
星期一, 十二月 5, 2022
Research, Women, Genetics, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, UPMC Hillman Cancer Center, Physician, Prognosis, Recurrence, 2009 Davis Cup, Hematology, Pediatric Hematology and Oncology, CT, Johns Hopkins University, MD, MD Anderson Cancer Center, University, American Journal of Clinical Oncology, Gene expression profiling, Transcriptome, Patient, Alvin J. Siteman Cancer Center, Science, Research, Biology, Genomics, Breast cancer, Professor, Assistant, Blueprint, Neoplasm, IDEAL, Woman, Oncology, UCSF, Surgeon, Behavior, Journal, Marie Cassidy, Growth, 2022 European Space Agency Astronaut Group, UPMC, NET, FLEX, Associate, Risk, Medical imaging, MammaPrint

Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • Three of the studies Agendia will present are based on its FLEX trial, the largest real-world evidence database of patients with early-stage breast cancer.
  • The research derived from our FLEX trial is a key example of the type of advancements in breast cancer Agendia is helping to fuel.
  • These critical discoveries will improve the future of personalized care for all women with breast cancer, including those who are often underrepresented in genomic studies, said William Audeh, MD, Chief Medical Officer at Agendia.

PrognomiQ Strengthens its Scientific and Clinical Leadership with the Appointment of Brian Koh, M.D. as Chief Medical Officer

Retrieved on: 
星期二, 十一月 29, 2022
Gilead Sciences, Proteomics, SAN, Transcriptome, Pharmacology, Genomics, Cancer, Yale University, Therapy, Epigenome, Oncology, Hotel manager, Biomarker, Internal medicine, Genome, Metabolomics, Medicine, Kite Pharma, Hematology, Health, Harvard College, Mayo, Metabolome, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., Nov. 29, 2022 /PRNewswire/ -- PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced that it has appointed Brian Koh, M.D., as its Chief Medical Officer. In this new role, Dr. Koh will be responsible for developing and executing the company's clinical development and medical strategy, serving on PrognomiQ's Executive Team.

Key Points: 
  • In this new role, Dr. Koh will be responsible for developing and executing the company's clinical development and medical strategy, serving on PrognomiQ's Executive Team.
  • Furthermore, Dr. Koh's addition to PrognomiQ's leadership team broadens the deep technical expertise of the company in proteomics, multi-omics and data sciences."
  • In furthering the company's commitment and leadership position in multi-omics, PrognomiQ also promoted Bruce Wilcox, Ph.D. to the position of Chief Technology Officer.
  • PrognomiQ uses leading edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health.

Next-Generation Sequencing Services Market is anticipated to grow at 15.4% CAGR till 2028, Says Brandessence Market Research

Retrieved on: 
星期四, 十一月 10, 2022
Ion semiconductor sequencing, Laboratory, Oxford Nanopore Technologies, Investment, Informatics, Partnership, Immunotherapy, Research, Gene, Abraxis BioScience, Transcriptome, ABI Solid Sequencing, Oncology, Attention, Biomarker, Cancer, Clinical trial, Public health, Patient, Growth, Asia-Pacific, NGS, FDA, Medical imaging, Fine chemical, Illumina

Asia Pacific is a market which is going to grow at the fastest as a revenue earner in the coming years.

Key Points: 
  • Asia Pacific is a market which is going to grow at the fastest as a revenue earner in the coming years.
  • This is going to grow the market significantly in the coming years particularly in the post pandemic period in Asia.
  • But the manufacturers have been strategizing constantly in their research and development for addressing the challenges.
  • On Special Requirement Next-Generation Sequencing Services Market Report is also available for below region:

Kernal Biologics Announces Presentations at The International mRNA Health Conference

Retrieved on: 
星期三, 十一月 9, 2022
R. Erdem Erkul, Spleen, Liver, Engineering, Patient, Blood, Cancer, RNA transfection, Immune system, Bone marrow, Transcriptome, LNP, Conference, Tissue, Survival rate, M.D, Social media, International, Quality of life, Multimedia, Therapy, Vaccine

CAMBRIDGE, Mass., Nov. 9, 2022 /PRNewswire/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced it will have three presentations at the International mRNA Health Conference being held in Boston and virtually from November 8th to 10th, 2022.   

Key Points: 
  • "We are delighted to present our work at this year's International mRNA Health Conference.
  • "In a preclinical study of KR-335, our tumor-selective mRNA LNP, we demonstrate tumor regression, improved overall survival and complete responses across different murine tumor models as a monotherapy."
  • "When expanding into therapeutic modalities, like cancer, universal translation of mRNA may become harmful.In another presentation, we demonstrate how it's possible to develop mRNA 2.0 - novel mRNA therapies using engineered mRNA molecules to translate in specific tissues and cell types.
  • Kernal Bio established a machine learning-backed computational pipeline to analyze transcriptome and translatome datasets across cell types and disease state to discover cell-specific mRNA sequence features.

Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Oncology, Health, Genetics, Health Technology, Pharmaceutical, Biotechnology, Annual general meeting, Informatics, U.S. Securities and Exchange Commission, Society, NGS, Antigen presentation, Biomarker, Immunotherapy, Cancer, Clinical Laboratory Improvement Amendments, Melanoma, Immune system, College of American Pathologists, SITC, Society for Immunotherapy of Cancer, Transcriptome, TME, TMB, 2021 Essex County Council election, Science, PSNL, Bias, Genomics, Doctor of Philosophy, NeXT, Leadership, Nasdaq, HIV disease progression rates, Efficiency, New Center, Detroit, Neoplasm, Tumor microenvironment, College, ICB, MHC, Medical imaging, Chief Justice of Hungary

Overview: Tumor neoantigen burden outperformed tumor mutational burden in prediction of patient response to checkpoint inhibitor immunotherapy by better capturing the biological mechanism underlying response.

Key Points: 
  • Overview: Tumor neoantigen burden outperformed tumor mutational burden in prediction of patient response to checkpoint inhibitor immunotherapy by better capturing the biological mechanism underlying response.
  • However, immune recognition of neoantigens by T-cells requires more than antigen presentation, which has been the focus of tumor neoantigen burden thus far.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.

Global RNA Analysis Market Report 2022: Single Cell Transcriptomics And Associated Big Data Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 7, 2022
Biotechnology, Genetics, Health, MicroRNA, RNA, Research, PCR, NGS, CD Genomics, Investment, Element, RNA transfection, Biotechnology, CAGR, Industry, Asia-Pacific, Biomarker, Application, Digital, Data management, COVID-19, Clifton Springs Hospital & Clinic, Cros, Transcriptomics technologies, Transcriptome, USFDA, USD, Drug development, Sequencing, Kits, Real-time, Union, Genomics, Gene, Patient, Hospital, Fine chemical, Pharmaceutical industry, Technology, Instrument

The global RNA analysis market size is anticipated to reach USD 42.30 billion by 2030, expanding at a CAGR of 16.59% from 2022 to 2030.

Key Points: 
  • The global RNA analysis market size is anticipated to reach USD 42.30 billion by 2030, expanding at a CAGR of 16.59% from 2022 to 2030.
  • Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA.
  • With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes.
  • For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.

First commercial kit to quantify protein modification in single cells launched by Singleron Biotechnologies

Retrieved on: 
星期四, 十一月 3, 2022
GLOBE, Transcriptome, RNA, Protein, Glycosylation, Research, Hospital, Laboratory, Gene expression, Solution, Fine chemical

COLOGNE, Germany, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Singleron Biotechnologies, a pioneer in development and commercialization of innovative single cell sequencing analysis solutions, announces the launch of the first commercially available product that can quantify protein glycosylation at single cell level, ProMoSCOPE kit.

Key Points: 
  • COLOGNE, Germany, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Singleron Biotechnologies, a pioneer in development and commercialization of innovative single cell sequencing analysis solutions, announces the launch of the first commercially available product that can quantify protein glycosylation at single cell level, ProMoSCOPE kit.
  • ProMoSCOPE makes it possible to obtain quantitative multimodal information on both glycosylation and gene expression from the same single cells.
  • Along with the rest of Singlerons single cell multi-omic portfolio, this new product adds to the toolbox to advance translational research.
  • Founded in 2018, Singleron develops and commercializes single-cell multi-omics products that can be used in both research and clinical settings.

Deepcell Expands Adoption of AI-Powered Morphology Characterization for Biological Researchers, Announces UCSF and TGen as First Installations in Technology Access Program

Retrieved on: 
星期二, 十一月 1, 2022
Software, Research, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Science, Biotechnology, Stem Cells, Other Science, Health, RNA, Hearing, Translational Genomics Research Institute, Breast cancer, G20 World Brain Mapping & Therapeutic Scientific Summit, IMA, Newcastle University, Research, Industry, TAP, Computational biology, Program, Disease, Proteome, Eye, Biophysics, Cell, Pathology, AI, Molecular biology, Bias, Cell biology, Technology, Adoption, University, Deep learning, Biochemistry, Transcriptome, Melanoma, Associate, University of California, San Francisco, B cell, City, Patient, UCSF, Medical laboratory, Genome, Biology, FCCF, City of Hope, Tumor microenvironment, CA, Mobile phone, Pharmaceutical industry, Medical imaging, Microscope

Using Deepcell technology, we aim to study time-course morphological changes in drugged lymphoblast cells.

Key Points: 
  • Using Deepcell technology, we aim to study time-course morphological changes in drugged lymphoblast cells.
  • Dr. Mark Magbanua, Laboratory Medicine at UCSF said, "We are excited to be a part of the technology access program to test Deepcell's platform.
  • Its exciting to begin operating the instrument in-house at TGen as a part of the Technology Access Program.
  • Scientists interested in hearing more about Deepcell technology or incorporating the Deepcell technology into their grants can reach out to Deepcell directly at: [email protected] .

Oxford Nanopore Technologies Announces New Collaboration With 10x Genomics to Make Single-cell and Spatial Full-length Isoform Transcript Sequencing Accessible to Any Laboratory

Retrieved on: 
星期四, 十月 27, 2022
Health, Technology, Other Technology, Genetics, Other Health, Biotechnology, Genomics, Cell biology, Embryonic development, Alternative splicing, Oxford Nanopore Technologies, Chromium, Spatial transcriptomics, Oxford, Scanning Flow Cell, DNA, CPP, Population, Genetics, Nanopore sequencing, Biology, Workflow, Nanopore, 10x Genomics, Research, Transcriptome, Atlas, USD, B cell, Antibiotics, Medical imaging

Oxford Nanopore Technologies plc (Oxford Nanopore) today announces a collaboration with 10x Genomics, to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.

Key Points: 
  • Oxford Nanopore Technologies plc (Oxford Nanopore) today announces a collaboration with 10x Genomics, to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.
  • The collaboration covers the addition of Oxford Nanopores PromethION devices and selected consumables, in conjunction with sample preparation on the 10x Genomics devices, into the 10x Genomics Compatible Partner Program (CPP).
  • Both parties believe this will enable a streamlined customer experience and highlight the compelling utility of nanopore-based sequencing in conjunction with 10x Genomics workflows.
  • Now, with Oxford Nanopore, 10x Genomics users can easily add a new dimension to their data using the fastest and most cost-effective full-length transcript sequencing approach.